+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bnp & Ntprobnp Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Bnp & Ntprobnp Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Bnp & Ntprobnp Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083861
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bnp & Ntprobnp Market grew from USD 1.96 billion in 2024 to USD 2.18 billion in 2025. It is expected to continue growing at a CAGR of 11.30%, reaching USD 3.73 billion by 2030.

The diagnostics of B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) play an increasingly pivotal role in cardiovascular care and chronic disease management. These biomarkers offer clinicians critical insights into heart failure progression, kidney dysfunction, and overall risk stratification. Advances in assay technologies, improvements in point-of-care solutions, and a heightened focus on personalized medicine have collectively transformed how practitioners interpret and act upon BNP and NT-proBNP levels. This executive summary outlines key developments shaping the market, dissects the effect of recent United States tariffs, and delivers actionable recommendations for healthcare providers, laboratories, and device manufacturers. By weaving together segmentation, regional and competitive insights, and targeted guidance, we present a comprehensive overview designed to inform strategic decisions and optimize patient outcomes.

Transformative Shifts in the BNP and NT-proBNP Diagnostics Landscape

The BNP and NT-proBNP diagnostics landscape has undergone transformative shifts fueled by technological innovation, evolving clinical guidelines, and changing patient expectations. Immunoassays have evolved from batch-based laboratory platforms to rapid point-of-care formats, enabling timely decision-making in emergency and outpatient settings. Microfluidics and biosensor integration have accelerated assay throughput while maintaining analytical precision. Clinicians now leverage high-sensitivity chemiluminescent immunoassays alongside traditional ELISA methods, ensuring both accuracy and turnaround speed.

Regulatory pathways have adapted to support rapid approval of novel diagnostic devices, reflecting a shift toward decentralized testing. Furthermore, digital health ecosystems now integrate assay data with electronic health records and remote monitoring tools, fostering personalized heart failure management plans. These strategic shifts underscore the transition from episodic testing toward continuous patient monitoring and proactive intervention. As a result, stakeholders across the value chain must realign investments in R&D, manufacturing capacity, and commercial strategies to capture emerging growth opportunities and meet the evolving needs of care teams and patients.

Cumulative Impact of United States Tariffs in 2025

In 2025, the implementation of United States tariffs on key diagnostic components and imported assay reagents accumulated into a significant cost burden across the BNP and NT-proBNP market. Manufacturers sourcing microfluidic chips, specialty reagents, and immunoassay antibodies from abroad experienced material cost increases that, when passed through the supply chain, impacted test kit pricing at both laboratory and point-of-care levels. The tariffs also disrupted established sourcing strategies, prompting suppliers to explore alternate manufacturing hubs in regions with more favorable trade agreements.

Clinical laboratories faced constrained budgets as procurement costs rose, while device makers accelerated partnerships with domestic reagent producers to mitigate exposure. This shift toward localized supply chains triggered new capital investments in production facilities but also introduced lead-time challenges during the transition period. Overall, the cumulative impact of the tariffs reinforced the strategic importance of supply-chain resilience, compelling industry participants to balance cost containment with the imperative to maintain assay quality and accessibility for patients.

Key Segmentation Insights

Detailed analysis of BNP and NT-proBNP market segmentation reveals diverse dynamics that shape competitive positioning and innovation priorities. When evaluating product type, test kit providers are refining formulations for both BNP Test Kits and NT-proBNP Test Kits to address varying sensitivity requirements and clinical indications. Within test type, laboratory testing remains anchored by high-throughput chemiluminescent immunoassays and enzyme-linked immunosorbent assays, while point-of-care testing evolves to deliver handheld and cartridge-based solutions for rapid triage.

Component segmentation highlights a bifurcation between analyzers and devices-ranging from benchtop systems to portable units-and reagents and kits optimized for specific assay platforms. Technological distinctions emerge across biosensor-based platforms, traditional immunoassays, and advanced microfluidic chips enabling multiplexed or ultra-low volume testing. Sales channels split between offline distribution networks established through clinical sales teams and growing online marketplaces that simplify reordering and inventory management.

Application areas underscore the utility of BNP and NT-proBNP measurements in heart failure management-covering acute presentations such as cardiogenic shock and decompensated heart failure, as well as chronic conditions that include biventricular and left- or right-sided dysfunction such as cor pulmonale-alongside kidney dysfunction settings encompassing acute kidney injury and chronic kidney disease. In risk assessment, assays support prognostic evaluation through mortality and readmission risk assessments, as well as screening protocols for broader cardiovascular disease prevention.

End-user segmentation illustrates strong demand in clinical laboratories-spanning diagnostic branches like biochemistry and pathology labs as well as research labs-to hospitals and clinics that deploy bedside testing, and research institutes and academic centers focused on biomarker discovery and validation.

Key Regional Insights

Regional performance in the BNP and NT-proBNP diagnostics arena reflects distinct healthcare priorities, infrastructure capabilities, and reimbursement landscapes. In the Americas, the market sustains momentum through robust cardiovascular disease screening programs, high adoption of point-of-care platforms, and a well-established distribution network bolstered by integrated health systems. Meanwhile, Europe, the Middle East & Africa exhibit a heterogeneous profile: Western European markets emphasize stringent regulatory compliance and high-sensitivity immunoassay uptake, while emerging markets in the Middle East and parts of Africa show growing investment in portable devices to support remote patient management.

In the Asia-Pacific region, surging incidences of heart failure and rising healthcare expenditure drive demand for both laboratory and point-of-care solutions. Local manufacturers in China, Japan, and South Korea are rapidly scaling production of reagents and benchtop analyzers, leveraging government incentives to expand domestic diagnostics capabilities. Simultaneously, online sales channels gain traction across urban and peri-urban centers, enhancing access and reducing procurement lead times for hospitals and independent laboratories.

Key Companies Insights

Competitive dynamics within the BNP and NT-proBNP space feature established diagnostics giants and agile specialty players. Abbott Laboratories continues to innovate in point-of-care immunoassays, while Autobio Diagnostics Co., Ltd. focuses on cost-competitive reagent kits. Beckman Coulter, Inc. and Roche lead the high-throughput immunochemistry segment with automated analyzers. Bio-Rad Laboratories, Inc. and bioMérieux PLC leverage strong distribution networks to reach niche research and clinical labs, whereas Chengdu Illumaxbio Technology Co., Ltd. and Fujirebio China Co., Ltd. target domestic expansion with localized reagent manufacturing.

Gentian Diagnostics ASA and Getein Biotech, Inc. push the envelope on rapid, portable biosensor platforms, contrasted by QuidelOrtho Corporation and Radiometer Medical ApS, which enhance point-of-care solutions with integrated patient data systems. Randox Laboratories Ltd. and Siemens AG maintain global footprints in sophisticated benchtop analyzers, while Sysmex Corporation and Thermo Fisher Scientific Inc. diversify across component portfolios to capture both device and reagent segments. Tosoh Europe N.V. solidifies its presence with robust ELISA offerings and reagents tailored for European regulatory standards.

Actionable Recommendations for Industry Leaders

To navigate the evolving BNP and NT-proBNP diagnostics market, industry leaders should pursue a multifaceted strategy focused on supply-chain robustness, technological differentiation, and customer engagement. First, forging strategic partnerships with reagent and component suppliers will insulate operations from tariff-driven cost fluctuations and ensure a steady flow of critical inputs. Second, investing in advanced biosensor research and microfluidic integration can deliver novel point-of-care assays that meet the growing demand for rapid, decentralized testing.

Third, aligning product development with regional healthcare priorities-such as tailoring assay sensitivity profiles for populations with distinct comorbidity patterns-will unlock new adoption opportunities. Fourth, enhancing digital service offerings, including outcome-driven analytics and remote monitoring dashboards, will solidify customer relationships and reinforce recurring revenue streams. Finally, expanding training and education programs for laboratory personnel and clinicians will foster deeper adoption of emerging BNP and NT-proBNP platforms.

Conclusion

The BNP and NT-proBNP diagnostics sector stands at the confluence of unmet clinical needs and rapid technological progress. By understanding the nuanced drivers within segmentation, regional landscapes, and competitive positioning, stakeholders can align resources to where clinical demand, cost efficiency, and innovation intersect most powerfully. Embracing supply-chain diversification, prioritizing high-impact R&D initiatives, and deepening engagement with healthcare providers will collectively enhance diagnostic accuracy and patient outcomes. Through disciplined execution of these insights, organizations will be well-positioned to lead in a market defined by precision, speed, and accessibility.

Market Segmentation & Coverage

This research report categorizes the Bnp & Ntprobnp Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Bnp Test Kits
  • Ntprobnp Test Kits
  • Laboratory Testing
    • Chemiluminescent Immunoassay (CLIA)
    • Enzyme-linked Immunosorbent Assay (ELISA)
  • Point-of-Care Testing
  • Analyzers & Devices
    • Benchtop Analyzers
    • Portable Analyzers
  • Reagents & Kits
  • Biosensors
  • Immunoassays
  • Microfluidics
  • Offline Sales
  • Online Sales
  • Heart Failure Management
    • Acute Heart Failure
      • Cardiogenic Shock
      • Decompensated Heart Failure
    • Chronic Heart Failure
      • Biventricular Heart Failure
      • Left-Sided Heart Failure
      • Right-Sided Heart Failure
        • Cor Pulmonale
  • Kidney Dysfunction
    • Acute Kidney Injury
    • Chronic Kidney Disease
  • Risk Assessment
    • Prognostic Evaluation
      • Mortality Risk Assessment
      • Readmission Risk Assessment
    • Screening for Cardiovascular Diseases
  • Clinical Laboratories
    • Diagnostic Laboratories
      • Biochemistry Labs
      • Pathology Labs
    • Research Laboratories
  • Hospitals & Clinics
  • Research Institutes & Academia

This research report categorizes the Bnp & Ntprobnp Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Bnp & Ntprobnp Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Autobio Diagnostics Co., Ltd.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc
  • bioMérieux PLC
  • Chengdu Illumaxbio Technology Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Fujirebio China Co., Ltd.
  • Gentian Diagnostics ASA
  • Getein Biotech, Inc.
  • QuidelOrtho Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Europe N.V.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bnp & Ntprobnp Market, by Type
8.1. Introduction
8.2. Bnp Test Kits
8.3. Ntprobnp Test Kits
9. Bnp & Ntprobnp Market, by Test Type
9.1. Introduction
9.2. Laboratory Testing
9.2.1. Chemiluminescent Immunoassay (CLIA)
9.2.2. Enzyme-linked Immunosorbent Assay (ELISA)
9.3. Point-of-Care Testing
10. Bnp & Ntprobnp Market, by Component
10.1. Introduction
10.2. Analyzers & Devices
10.2.1. Benchtop Analyzers
10.2.2. Portable Analyzers
10.3. Reagents & Kits
11. Bnp & Ntprobnp Market, by Technology
11.1. Introduction
11.2. Biosensors
11.3. Immunoassays
11.4. Microfluidics
12. Bnp & Ntprobnp Market, by Sales Channel
12.1. Introduction
12.2. Offline Sales
12.3. Online Sales
13. Bnp & Ntprobnp Market, by Application
13.1. Introduction
13.2. Heart Failure Management
13.2.1. Acute Heart Failure
13.2.1.1. Cardiogenic Shock
13.2.1.2. Decompensated Heart Failure
13.2.2. Chronic Heart Failure
13.2.2.1. Biventricular Heart Failure
13.2.2.2. Left-Sided Heart Failure
13.2.2.3. Right-Sided Heart Failure
13.2.2.3.1. Cor Pulmonale
13.3. Kidney Dysfunction
13.3.1. Acute Kidney Injury
13.3.2. Chronic Kidney Disease
13.4. Risk Assessment
13.4.1. Prognostic Evaluation
13.4.1.1. Mortality Risk Assessment
13.4.1.2. Readmission Risk Assessment
13.4.2. Screening for Cardiovascular Diseases
14. Bnp & Ntprobnp Market, by End User
14.1. Introduction
14.2. Clinical Laboratories
14.2.1. Diagnostic Laboratories
14.2.1.1. Biochemistry Labs
14.2.1.2. Pathology Labs
14.2.2. Research Laboratories
14.3. Hospitals & Clinics
14.4. Research Institutes & Academia
15. Americas Bnp & Ntprobnp Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Bnp & Ntprobnp Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Bnp & Ntprobnp Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. Autobio Diagnostics Co., Ltd.
18.3.3. Beckman Coulter, Inc.
18.3.4. Bio-Rad Laboratories, Inc
18.3.5. bioMérieux PLC
18.3.6. Chengdu Illumaxbio Technology Co., Ltd.
18.3.7. F. Hoffmann-La Roche Ltd
18.3.8. Fujirebio China Co., Ltd.
18.3.9. Gentian Diagnostics ASA
18.3.10. Getein Biotech, Inc.
18.3.11. QuidelOrtho Corporation
18.3.12. Radiometer Medical ApS
18.3.13. Randox Laboratories Ltd.
18.3.14. Siemens AG
18.3.15. Sysmex Corporation
18.3.16. Thermo Fisher Scientific Inc.
18.3.17. Tosoh Europe N.V.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. BNP & NTPROBNP MARKET MULTI-CURRENCY
FIGURE 2. BNP & NTPROBNP MARKET MULTI-LANGUAGE
FIGURE 3. BNP & NTPROBNP MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BNP & NTPROBNP MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BNP & NTPROBNP MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BNP & NTPROBNP MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BNP & NTPROBNP MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. BNP & NTPROBNP MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. BNP & NTPROBNP MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BNP & NTPROBNP MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BNP & NTPROBNP MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BNP & NTPROBNP MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BNP TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BNP & NTPROBNP MARKET SIZE, BY NTPROBNP TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY (CLIA), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BNP & NTPROBNP MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BNP & NTPROBNP MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BNP & NTPROBNP MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BNP & NTPROBNP MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BNP & NTPROBNP MARKET SIZE, BY OFFLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CARDIOGENIC SHOCK, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BNP & NTPROBNP MARKET SIZE, BY DECOMPENSATED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BIVENTRICULAR HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BNP & NTPROBNP MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BNP & NTPROBNP MARKET SIZE, BY COR PULMONALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BNP & NTPROBNP MARKET SIZE, BY ACUTE KIDNEY INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BNP & NTPROBNP MARKET SIZE, BY MORTALITY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BNP & NTPROBNP MARKET SIZE, BY READMISSION RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BNP & NTPROBNP MARKET SIZE, BY SCREENING FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BNP & NTPROBNP MARKET SIZE, BY BIOCHEMISTRY LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BNP & NTPROBNP MARKET SIZE, BY PATHOLOGY LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BNP & NTPROBNP MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BNP & NTPROBNP MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 118. CANADA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. CANADA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 120. CANADA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 121. CANADA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 122. CANADA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 123. CANADA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. CANADA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. CANADA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. CANADA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 127. CANADA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 128. CANADA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 129. CANADA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 130. CANADA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 131. CANADA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 132. CANADA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 133. CANADA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. CANADA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 135. CANADA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BNP & NTPROBNP MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BNP & NTPROBNP MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 210. CHINA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 211. CHINA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 212. CHINA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 213. CHINA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 214. CHINA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 215. CHINA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. CHINA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. CHINA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. CHINA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 219. CHINA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 220. CHINA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 221. CHINA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 222. CHINA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 223. CHINA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 224. CHINA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 225. CHINA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. CHINA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 227. CHINA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 228. INDIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. INDIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 230. INDIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 231. INDIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 232. INDIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 233. INDIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 234. INDIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. INDIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. INDIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 237. INDIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 238. INDIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 239. INDIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 240. INDIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 241. INDIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 242. INDIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 243. INDIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. INDIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 245. INDIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 256. INDONESIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 257. INDONESIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 261. INDONESIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 264. JAPAN BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 265. JAPAN BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 266. JAPAN BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 267. JAPAN BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 268. JAPAN BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 269. JAPAN BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. JAPAN BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. JAPAN BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. JAPAN BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 273. JAPAN BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 274. JAPAN BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 275. JAPAN BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 276. JAPAN BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 277. JAPAN BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 278. JAPAN BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 279. JAPAN BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. JAPAN BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 281. JAPAN BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 303. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 304. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 305. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 306. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 308. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 309. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 310. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 311. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 312. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 313. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 314. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 315. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 317. PHILIPPINES BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 318. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 319. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 320. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 321. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 322. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 323. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 324. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 326. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 327. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 328. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 329. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 330. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 331. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 332. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY PROGNOSTIC EVALUATION, 2018-2030 (USD MILLION)
TABLE 333. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY CLINICAL LABORATORIES, 2018-2030 (USD MILLION)
TABLE 335. SINGAPORE BNP & NTPROBNP MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 336. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 337. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 338. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY ANALYZERS & DEVICES, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY HEART FAILURE MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY ACUTE HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 346. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY CHRONIC HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 347. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 348. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY KIDNEY DYSFUNCTION, 2018-2030 (USD MILLION)
TABLE 349. SOUTH KOREA BNP & NTPROBNP MARKET SIZE, BY RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 350.

Companies Mentioned

  • Abbott Laboratories
  • Autobio Diagnostics Co., Ltd.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc
  • bioMérieux PLC
  • Chengdu Illumaxbio Technology Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Fujirebio China Co., Ltd.
  • Gentian Diagnostics ASA
  • Getein Biotech, Inc.
  • QuidelOrtho Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Europe N.V.

Methodology

Loading
LOADING...

Related Topics

Related Reports

BNP and NTproBNP Market Report 2025 - Product Image

BNP and NTproBNP Market Report 2025

  • Report
  • 200 Pages
  • Global
From
BNP And NTproBNP Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F - Product Image

BNP And NTproBNP Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Cardiac Biomarker Market by Biomarker Type (BNP & NT-proBNP, Creatine Kinase (CK) MB, Myoglobin), Clinical Setting (Laboratory Testing, Point Of Care Testing), Application, End User - Global Forecast 2025-2030 - Product Image

Cardiac Biomarker Market by Biomarker Type (BNP & NT-proBNP, Creatine Kinase (CK) MB, Myoglobin), Clinical Setting (Laboratory Testing, Point Of Care Testing), Application, End User - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031 - Product Image

Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031

  • Report
  • 165 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.